(3 years ago)
Commons ChamberMy hon. Friend is right to point to the continued importance of the vaccination programme. There are some 5 million people in the UK who have not received a single shot of any type of vaccine. He is right to talk about the importance of the delivery methods of a vaccine and, as he has mentioned, there are trials of nasal vaccines. However, I am sure he will understand that until such vaccines are approved by our independent regulator, we will not be able to pursue them.
I thank the Secretary of State, the NHS and everyone responsible for the booster programme that is helping to protect us as we enter the winter months, but is not one of the lessons of the news he has announced today that, if we do not tackle the enormous vaccine inequality around the world, we will continue to be exposed to new variants of this type? In Africa, for example, just 6.6% of the population have been vaccinated. Of course, it is every Government’s first duty to protect its own people—everyone understands that—but does he agree that the United Kingdom and other rich countries in the world must do more to ensure that surplus doses that we do not need are distributed to countries that do need them, rather than not being used and ultimately, in some cases, destroyed?
I very much agree with every word the right hon. Gentleman says, especially about surplus vaccines. That is exactly what we have done: whenever we have identified vaccines we may not need, we have offered them either bilaterally or through the COVID-19 Vaccines Global Access, or COVAX, programme. We will continue to play our role but, importantly, we will also continue to urge our international partners to do all they can as well.
(3 years ago)
Commons ChamberAs always, my right hon. Friend makes an important point. I will not go through the arguments why vaccination, whether of social care or NHS workers, is so important, although of course patient safety is central to that. However, he is right to ask what can be done about the pressures on the social care system, and to point to the important question of discharge from hospitals, among other issues. We are giving record amounts of support to the adult social care sector. The funding is a huge part of that—not only funding going into the sector to build capacity, but funding going to the NHS through the discharge fund, which is hundreds of millions of pounds it can use to support early discharge into care homes.
When the Secretary of State was appointed, he talked about tackling the “disease of disparity” and the inequalities in healthcare that had been exposed by the covid pandemic. Today, the sickle cell and thalassaemia all-party parliamentary group, which I chair, has published a major report on the care of people with sickle cell. The report exposes major inequalities and disparities, leading to people having to fight for the pain relief to which they are entitled, constantly having to explain their condition and developing a degree of mistrust in the healthcare system that is there to help them. We will send the Secretary of State a copy. Will he agree to meet me and representatives of the Sickle Cell Society to discuss the report’s findings?
Yes; I would be very happy to have that meeting with the right hon. Gentleman, because this is an important issue. While I have not yet read the entire report, I read the summary this morning, and it raises some important issues. If we are to properly tackle the disparities we see in this country, it is important that we look at all the proper research that has been done on them.